ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KEQU / insiders
BNR (20) SERA (29) XGN (36) TLSI (30) ⌘ Pro Terminal →

Kewaunee Scientific Corporation (KEQU) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$33.40 -0.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $33.33

Kewaunee Scientific Corporation (KEQU) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $96.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KEQU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.40 (-0.12% 1D, market cap $96.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #87 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KEQU compare to BNR and SERA in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, BNR (Burning Rock Biotech Limited) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $115.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $80.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KEQU?
▼

Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $33.33 (-0.21%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 6.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-
Cash (17)Whales (6)SEC (16)Macro (12)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$46 Bull$35 Base$27 Bear
📬 FREE KEQU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KEQU)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY KEQU SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 6.6% FCF Margin ($18.6M FCF) & 28.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$32.20+2.2% Next Q
Q2 (-2Q)
64
Grade C+$32.92+0.9% Next Q
Q3 (-1Q)
66
Grade B-$33.23+0.5% Next Q
Current
69
Grade C+$33.40+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KEQU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, KEQU faces multiple-compression risk if 10.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 26.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.46) or 200D SMA ($36.77) invalidates the momentum regime and cuts Target Base ($35.05) toward Bear Floor ($27.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KEQU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KEQU Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

KEQU Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (KEQU)

No recent open-market Form 4 cluster sales or emergency dumps flagged on KEQU. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (KEQU Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KEQU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.45%▼ DESCENDING CHANNEL
2026-11-03O $33.51H $33.51L $33.40C $33.40VOL 10.1K
RES: $37.28SUP: $31.11SMA50: $34.46SMA200: $36.77
$43.38$40.30$37.21$34.13$31.04RES $37.28SUP $31.11$33.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KEQU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KEQU Butterfly Map → + Track KEQU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-1.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KEQU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KEQU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KEQU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KEQU)

Health Care Rank #87 of 1016 ⚔️ BNR vs KEQU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KEQU vs. BNR, SERA, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kewaunee Scientific Corporation (KEQU) ranks #87 by composite RQD confidence (69/100, grade C+) and #660 by equity capitalization ($96.8M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KEQU ACTIVE
Kewaunee Scientific Corporation
C+ 69/100 10.1x 28.5% 16.7% -0.12% $96.8M Benchmark Subject
BNR
Burning Rock Biotech Limited
E 20/100 — 74.7% -35.0% -7.89% $115.0M /bnr-vs-kequ →
SERA
Sera Prognostics Inc. (Class A)
E 29/100 — -30.0% -35.0% -2.45% $80.5M /sera-vs-kequ →
XGN
Exagen Inc.
D- 36/100 — 58.3% -35.0% -2.33% $208.1M /xgn-vs-kequ →
TLSI
TriSalus Life Sciences Inc.
E 30/100 — 84.6% -35.0% -1.89% $227.8M /tlsi-vs-kequ →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0000055529

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kewaunee Scientific Corporation (KEQU) reported GAAP revenue of $282.0M (+17.3% vs. FY2024 revenue of $240.5M , and +38.4% cumulative change since FY2023) , GAAP net income of $9.6M, operating cash flow of $18.6M, and free cash flow of $18.6M (+26.0% YoY). On the balance sheet, KEQU closed FY2025 with $176.0M in total assets against $16.3M in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $282.0M $9.6M $18.6M $18.6M $176.0M $16.3M
FY2024 (FY) 2025-04-30 $240.5M $11.4M $14.8M $14.8M $189.1M $35.0M
FY2023 (FY) 2024-04-30 $203.8M $18.8M $19.6M $19.6M — —

3. KEQU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.40 (-0.12% 1D, market cap $96.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #87 in composite RQD confidence.

How does KEQU compare to BNR and SERA in the Health Care sector?

Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, BNR (Burning Rock Biotech Limited) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $115.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $80.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KEQU?

Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KEQU trading relative to its 50-day, 200-day, and 52-week technical levels?

KEQU last traded at $33.40 (-0.12% on volume of 21,172 shares), positioning the stock -3.08% below its 50-day simple moving average ($34.46) and -9.17% below its 200-day simple moving average ($36.77). Across its 52-week range of $32.00 to $43.36, KEQU sits at the 12.3% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±4.8% ($31.80 to $35.00).

Direct Sub-Reports: KEQU RQD Cockpit KEQU 12M Forecast KEQU Earnings & Move KEQU Dividends & DRIP KEQU Insiders & 13F KEQU Whale Options KEQU Profit Sankey KEQU News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

KEQU — Kewaunee Scientific Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kewaunee Scientific Corporation (KEQU) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $33.40 (-0.12% 1D, market capitalization $96.8M).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 16.7%, gross margin of 28.5%, operating margin of 5.9%, and free cash flow yield of 19.20%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.37, Piotroski F-Score of 8/9, and Debt/Equity of 0.23x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kewaunee Scientific Corporation is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry. Per the FY 2025 filing, revenue was $282.0M, indicating an operating scale in that range.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), Kewaunee Scientific Corporation (KEQU) reported $282.0M in annual revenue (up from $240.5M in FY2024, +17.3% YoY) and $9.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($203.8M revenue, $18.8M net income) through FY2025, KEQU scaled operating cash flow to $18.6M and free cash flow to $18.6M, backed by $176.0M in total assets against $16.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $32.00 – $43.36 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 10.1x trailing P/E and 6.3x EV/EBITDA against 5.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), KEQU carries a macro regime beta of 1.00 and gross margin of 28.5%.

  • Key Question #1: Can KEQU sustain or expand its 5.9% operating margin and 16.7% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $282.0M and free cash flow of $18.6M, how will capital allocation balance growth reinvestment against $16.3M in total debt?
  • Key Question #3: How sensitive is KEQU's 8.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KEQU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kewaunee Scientific Corporation (KEQU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KEQU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KEQU Bull vs. Bear Conversation Board — What's Your Call at $33.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KEQU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KEQU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $42.13 (+26.0%)
📌 Pinned Debate

A 19.2% FCF yield and 16.7% ROIC at a 10.1 trailing P/E suggest strong cash generation relative to the market value.

Long KEQU at $33.44 targeting $42.13. A 19.2% FCF yield and 16.7% ROIC at a 10.1 trailing P/E suggest strong cash generation relative to the market value.. Institutional whale score is 6/20 and the risk/reward vs. the $32.00 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@DeltaGamma_99 Agree on the RQD 69/100 quality, though with 1.0 beta I'm scaling in with half-size at $33.44 and keeping dry powder in case we test $31.10.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $25.41 (-24.0%)
Spot @ $33.44

Net income fell from $18.8M in FY 2023 to $9.6M in FY 2025 while a $55M acquisition is pending against $8.2M of cash.

Fading this rally in KEQU at $33.44. Net income fell from $18.8M in FY 2023 to $9.6M in FY 2025 while a $55M acquisition is pending against $8.2M of cash.. With a beta of 1.0 and the stock sitting at $33.44 (52-wk range $32.00–$43.36), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%